Clinical Research Boldocynara

Metabolic syndrome, a cluster of conditions including obesity, hyperglycemia, hypertension, and dyslipidemia, is a growing global health concern. The needfor well-tolerated, cost-effective interventions has driven research into botanical solutions. Boldocynara, a proprietary blend of Cynara scolymus (artichoke), Silybum marianum (milk thistle), Taraxacum officinale (dandelion), and Peumus boldus (boldo), has shown potential in modulating key metabolic pathways. Two key studies, conducted by Villiger et al. (2015) and Bommer et al. (2013), provide insights into the efficacy, safety, and mechanisms of action of Boldocynara in these contexts.

Study 1: Villiger et al. (2015) – Metabolic Syndrome and Enzyme Inhibition

This in vitro study evaluated the inhibitory effects of Boldocynara and its components on enzymes linked to metabolic syndrome, including blood sugar regulation, fat metabolism, oxidative stress, and cardiovascular health.

Methodology:

  • Study Type: In vitro enzyme inhibition assays
  • Key Outcome Measures: Enzyme inhibition at concentrations of 10-100 µg/mL

Results:

  • α-Glucosidase Inhibition: Boldo exhibited the strongest inhibition (IC50: 17.56 µg/mL), suggesting a role in blood sugar regulation.
  • Pancreatic Lipase Inhibition: Boldo and milk thistle showed moderate inhibition (~30% at 100 µg/mL), indicating potential in weight management.
  • Xanthine Oxidase Inhibition: Boldo reduced enzyme activity by 25-27%, supporting its potential role in oxidative stress mitigation.
  • ACE Inhibition: Artichoke displayed moderate ACE inhibition (~30% at 5 µg/mL), suggesting cardiovascular benefits.
Link to full study

Study 2: Bommer et al. (2013) – Functional Digestive Disorders

This multicentric clinical trial evaluated the safety and efficacy of Boldocynara in patients with functional digestive disorders over a six-week period.

Methodology:

Study Type: Multicentric, open-label clinical safety trial

Participants: 75 adults (ages 18-70) with at least three functional digestive symptoms occurring twice weekly for at least two months.

Treatment Regimen: Boldocynara tablets taken twice daily for six weeks.

Key Outcome Measures:

  • Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ)
  • Global Gastrointestinal Symptom Questionnaire
  • Quality of Life (QoL SF-12) assessment
  • Physician and patient evaluations of tolerability

Results:

Reduction in Digestive Symptoms:

  • SF-LDQ sum score for dyspeptic symptoms dropped from 6.3±2.9 to 1.4±2.0 (p < 0.0001).
  • Significant reduction in heartburn, regurgitation, nausea, bloating, and constipation (p < 0.0001).

Improvement in Quality of Life:

  • Statistically significant improvement across all QoL-SF-12 parameters.

Safety and Tolerability:

  • 89% of physicians and 91% of patients rated tolerability as ‘good’ or ‘very good’.
  • Only two mild adverse events (loss of appetite and abdominal distension) were reported.
  • No clinically relevant changes in laboratory safety parameters.
Link to full study

Mechanism of Action

The efficacy of Boldocynara in both metabolic and digestive health can be attributed to its multi-targeted mechanisms:

  • Blood Sugar and Lipid Regulation: Boldo’s strong α-glucosidase and pancreatic lipase inhibition suggests a role in reducing postprandial glucose spikes and improving fat metabolism.
  • Liver and Gallbladder Support: Artichoke stimulates bile production, enhancing fat digestion and liver detoxification.
  • Antioxidant and Anti-Inflammatory Effects: Milk thistle and boldo support oxidative stress reduction and metabolic health.
  • Gastrointestinal Function: Dandelion and boldo promote smooth digestion, reducing bloating and irregular bowel movements.
  • Cardiovascular Support: Moderate ACE inhibition by artichoke suggests potential benefits for blood pressure regulation.

Summary

The combined findings from Villiger et al. (2015) and Bommer et al. (2013) demonstrate that Boldocynara is a well-tolerated and effective botanical formulation for managing both metabolic syndrome-related concerns and functional digestive disorders. The in vitro study highlights its potential in enzyme modulation, while the clinical trial confirms its efficacy in symptom relief and quality of life improvements. These results suggest that Boldocynara offers a promising natural alternative for individuals seeking metabolic and digestive health support. Future research, including more controlled human trials, could further clarify its full therapeutic potential.

1 4

A.Vogel Digestive Aid Complex - Relieves Digestive Disturbances 60 Tabs

View full details